Integrins are a class of transmembrane receptors that are involved in a wide range of biological functions. Dysregulation of integrins has been implicated in many pathological processes and consequently, they are attractive therapeutic targets. In the ophthalmology arena, there is extensive evidence suggesting that integrins play an important role in diabetic retinopathy (DR), age-related macular degeneration (AMD), glaucoma, dry eye disease and retinal vein occlusion. For example, there is extensive evidence that arginyl-glycyl-aspartic acid (Arg-Gly-Asp; RGD)-binding integrins are involved in key disease hallmarks of DR and neovascular AMD (nvAMD), specifically inflammation, vascular leakage, angiogenesis and fibrosis. Based on such evidence, drugs that engage integrin-linked pathways have received attention for their potential to block all these vision-threatening pathways.

This review focuses on the pathophysiological role that RGD-binding integrins can have in complex multifactorial retinal disorders like DR, diabetic macular edema (DME) and nvAMD, which are leading causes of blindness in developed countries. Special emphasis will be given on how RGD-binding integrins can modulate the intricate molecular pathways and regulate the underlying pathological mechanisms. For instance, the interplay between integrins and key molecular players such as growth factors, cytokines and enzymes will be summarized. In addition, recent clinical advances linked to targeting RGD-binding integrins in the context of DME and nvAMD will be discussed alongside future potential for limiting progression of these diseases.

整合素是一类涉及广泛生物学功能的跨膜受体。整合素的失调与许多病理过程有关，因此，它们是有吸引力的治疗靶点。在眼科领域，有大量证据表明整合素在糖尿病视网膜病变 (DR)、年龄相关性黄斑变性 (AMD)、青光眼、干眼病和视网膜静脉阻塞中发挥重要作用。例如，有大量证据表明，精氨酰-甘氨酰-天冬氨酸 (Arg-Gly-Asp; RGD) 结合整联蛋白与 DR 和新生血管性 AMD (nvAMD) 的关键疾病标志有关，特别是炎症、血管渗漏、血管生成和纤维化. 基于这样的证据，

本综述侧重于 RGD 结合整联蛋白在复杂的多因素视网膜疾病（如 DR、糖尿病性黄斑水肿 (DME) 和 nvAMD）中的病理生理学作用，这些疾病是发达国家失明的主要原因。将特别强调 RGD 结合整合素如何调节复杂的分子途径并调节潜在的病理机制。例如，将总结整合素与生长因子、细胞因子和酶等关键分子参与者之间的相互作用。此外，在 DME 和 nvAMD 的背景下，与靶向 RGD 结合整联蛋白相关的近期临床进展将与限制这些疾病进展的未来潜力一起讨论。